Trial record 13 of 20 for:
Open Studies | "Scleroderma, Localized"
Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
This study is currently recruiting participants.
Verified February 2013 by Mayo Clinic
Sponsor:
Mayo Clinic
Information provided by (Responsible Party):
Augustine S. Lee, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01667042
First received: August 14, 2012
Last updated: February 25, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a mechanistic research study to evaluate the relationship between cough, reflux, and aspiration in patients with systemic sclerosis (scleroderma).
| Condition |
|---|
|
Scleroderma Lung |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough |
Resource links provided by NLM:
Further study details as provided by Mayo Clinic:
| Estimated Enrollment: | 12 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Without Interstitial lung disease (ILD) |
| With Interstitial lung disease (ILD) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
All consecutive adult patients seen at the Mayo Clinic in Florida with a confirmed diagnosis of systemic sclerosis (SSc) will be eligible.
Criteria
Inclusion Criteria:
- Adult patients ≥ 18 years old.
- Fulfilling the American College of Rheumatology criteria for SSc.
For ILD subgroup (n=6):
- An upright chest-roentgenogram (chest x-ray) is abnormal and compatible with an interstitial lung disease.
- HRCT of the chest confirms the presence of bilateral reticular, ground glass, and/or honeycomb abnormalities that is otherwise unexplained by an alternative process
- The HRCT fibrosis score must be ≥ 7.
- The total lung capacity (TLC, measured by body plethysmography) and/or the diffusing capacity of the lung for carbon monoxide (DLCO) is below the predicted normal.
- The forced vital capacity (FVC) is reduced below the predicted normal.
- The patient is symptomatic (i.e. dyspnea and/or a chronic cough) for more than 8 weeks that is otherwise unexplained by an alternative mechanism.
For No ILD subgroup (n=6):
- No radiographic evidence of ILD on plain chest x-ray.
- The HRCT fibrosis score, when performed) must be < 7
- The TLC and FVC are within their predicted normal.
- The DLCO is within the predicted normal, except when reduced in isolation by pulmonary hypertension.
Exclusion Criteria:
- Active smoking within the 6 months.
- Pneumonia or bronchitis in past 4 weeks.
- Active acute illness such as uncontrolled heart failure, infection, or asthma.
- Use of more than 3 liters per minute (LPM) of oxygen by nasal cannula at rest.
- Coordinator, investigator, or clinician concerns on the patient's compliance, safety, or in ability to complete study requirements.
- Morbid condition not expected to live more than 1 year.
- Alternative cause or diagnosis for the patient's ILD besides SSc.
- Pregnancy.
- Obstructive lung disease with an FEV1 (forced expiratory volume in 1 second) to FVC ratio less than 0.7, nor radiographic evidence of emphysema on CT.
- Planned therapeutic procedures involving the esophagus (e.g. dilation, surgery) prior to completion of study tests
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01667042
Contacts
| Contact: Kellie Ruday | 904-953-7766 | ruday.kellie@mayo.edu |
Locations
| United States, Florida | |
| Mayo Clinic in Florida | Recruiting |
| Jacksonville, Florida, United States, 32224 | |
| Contact: Kellie Ruday 904-953-7766 ruday.kellie@mayo.edu | |
| Principal Investigator: Augustine Lee, M.D. | |
Sponsors and Collaborators
Mayo Clinic
Investigators
| Principal Investigator: | Augustine Lee, M.D. | Mayo Clinic |
More Information
No publications provided
| Responsible Party: | Augustine S. Lee, M.D., Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT01667042 History of Changes |
| Other Study ID Numbers: | 12-000304 |
| Study First Received: | August 14, 2012 |
| Last Updated: | February 25, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Mayo Clinic:
|
Scleroderma Lung Gastroesophageal Reflux Microaspiration Cough |
Additional relevant MeSH terms:
|
Scleroderma, Localized Scleroderma, Systemic Scleroderma, Diffuse Gastroesophageal Reflux Connective Tissue Diseases Skin Diseases |
Esophageal Motility Disorders Deglutition Disorders Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013